Efficacy and safety of thalidomide in the treatment of multiple myeloma

Acta Poloniae Pharmaceutica - Drug Research

Volumn 65, Issue 6, 2008, Pages 771-774

  Warzocha, Krzysztof ^a   Kraj, Maria ^a   Pogłód, Ryszard ^a   Szpila, Tomasz ^a   Mendek Czajkowska, Ewa ^a   Chełstowska, Monika ^a   Tronina, Renata Hagedorna ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Multiple myeloma; Thalidomide

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MYRIN; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADAMS STOKES ATTACK; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; HEARING LOSS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLASMA CELL LEUKEMIA; PNEUMONIA; SENSORY NEUROPATHY; SINUS BRADYCARDIA; SKIN DEFECT; SOMNOLENCE; SYNCOPE; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RECURRENT DISEASE; TIME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 61549112765     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Barlogie B., Desikan R., Eddelmon P. et al.: Blood 98, 492 (2001).
2. Glasmacher A., Hahn C., Hoffmann F. et al.: Br. J. Haematol. 132, 584 (2005).
3. Bamias A., Dimopoulos M.A.: Expert Opin. Investig. Drugs 14, 45 (2005).
4. Dimopoulos M.A., Hamilos G., Zomas A. et al.: Hematol. J. 5, 112 (2004).
5. Palumbo A., Bringhen S., Caravita T. et al.: Lancet 367, 825 (2006).
6. Facon T., Mary J.Y., Hulin C. et al.: Lancet 370, 1209 (2007).
7. Cavo M., Zamagni E., Tosi P. et al.: Blood 106, 35 (2005).
8. Rajkumar S.V., Blood E., Vesole D. et al.: J. Clin. Oncol. 24, 431 (2006).
9. Hideshima T., Chauhan D., Podar K. et al.: Semin. Oncol. 28., 607 (2001).
10. Kraj M., Szpila T., Chełstowska M. et al.: Haematologica 92 Suppl. 2, 168 (2007).
11. Durie B.G.M., Harousseau J-L., Miguel J.S. et al.: Leukemia 20, 1467 (2006).
12. Fahdi I.E., Gaddam V., Saucedo J.F. et al.: Am. J. Cardiol. 93, 1052 (2004).
13. Ballanti S., Mastrodicasa E., Bolli N. et al.: Nat. Clin. Pract. Oncol. 4, 722 (2007).
14. Orea-Tejeda A., Arrieta-Rodriguez O., Castillo- Martinez L. et al.: Cardiology 108, 237 (2007).
15. Gullestad L., Semb A.G., Holt E. et al.: Am. Heart J. 144, 847 (2002).
16. Rajkumar S.V., Gertz M.A., Lacy M.Q. et al.: Leukemia 17, 775 (2003).
17. Alexandrescu D.T., Koulova L., Wiernik P.H.: Clin. Exp. Dermatol. 30, 391 (2005).
18. Saba S., Epstein A., Niesvizky R., Coleman M.: Haematologica 90 Suppl. 1, 143 (2005).
19. Avigdor A., Raanani P., Levi I. et al.: Leuk. Lymphoma 42, 683 (2001).
20. Bladé J., Perales M., Rosinol L. et al.: Br. J. Haematol. 113, 422 (2001).